Is hepatic steatosis associated with left ventricular mass index increase in the general population?

about

Is hepatic steatosis associated with left ventricular mass index increase in the general population?

Item

http://www.wikidata.org/entity/Q38663332

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Is hepatic steatosis associate ...... ase in the general population?

@en

type

Item

label

Is hepatic steatosis associate ...... ase in the general population?

@en

prefLabel

Is hepatic steatosis associate ...... ase in the general population?

@en

P1476

Is hepatic steatosis associate ...... ase in the general population?

@en

P2093

Henry Völzke

http://www.w3.org/2001/XMLSchema#string

Katharina Piontek

http://www.w3.org/2001/XMLSchema#string

Sebastian E Baumeister

http://www.w3.org/2001/XMLSchema#string

Stephan B Felix

http://www.w3.org/2001/XMLSchema#string

P2860

Menopausal status and hepatic steatosis in a general female population

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.

The spectrum of liver disease in the general population: lesson from the Dionysos study.

Hepatic steatosis is associated with an increased risk of carotid atherosclerosis.

Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance

Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes.

Influence of Physical Activity on Hypertension and Cardiac Structure and Function

Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT).

P304

857-866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4254/WJH.V9.I19.857

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Carsten Oliver Schmidt

Markus M Lerch

Marcus Dörr

Julia Mayerle

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28740597

http://www.w3.org/2001/XMLSchema#string

P932

5504361

http://www.w3.org/2001/XMLSchema#string